CSPC Pharmaceutical Group Limited (CSPCY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY bn | 25 | 28 | 31 | 35 | 29 | 25 | 31 | - |
| Operating profit | CNY bn | 4 | 9 | ||||||
| Net profit | CNY bn | 4 | 6 | 6 | 6 | 4 | 4 | 7 | - |
| EPS reported | CNY | 1.32 | 2.60 | ||||||
| Operating cashflow per share | CNY | 2.04 | 0.97 | ||||||
| Capex per share | CNY | 0.80 | 0.27 | ||||||
| FCF per share | CNY | 1.24 | 0.70 | ||||||
| Free cash flow | CNY bn | 4 | 12 | ||||||
| Net debt | CNY bn | -9 | -18 | ||||||
| Book value equity | CNY bn | 33 | 38 | ||||||
| Book value per share | CNY | 11.62 | 13.18 | ||||||
| Number of shares | m | 2,855.92 | 2,854.98 | ||||||
| DPS (TTM paid) | CNY | 1.03 | 1.65 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 22.84 | - | ||||||
| P/B LTM | x | 2.89 | 2.55 | ||||||
| P/S LTM | x | 3.79 | 3.10 | ||||||
| P/FCF LTM | x | 26.98 | 7.84 | ||||||
| EV/EBITDA LTM | x | 17.27 | 9.03 | ||||||
| EV/Sales LTM | x | 3.57 | 2.76 | ||||||
| Earnings Yield LTM | % | +4.38% | +7.76% | ||||||
| FCF Yield | % | +3.71% | +12.76% | ||||||
| Quality | |||||||||
| ROE | % | +11.37% | +20.68% | ||||||
| ROIC | % | +8.42% | +17.35% | ||||||
| Operating margin | % | +15.27% | +27.95% | ||||||
| Gross margin | % | +65.59% | +71.86% | ||||||
| FCF/Sales | % | +14.04% | +6.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -10.81% | +75.68% | ||||||
| Sales Growth YoY | % | -12.77% | +6.53% | ||||||
| Net Income Growth YoY | % | -12.72% | +69.61% | ||||||
| FCF Growth | % | +103.74% | +601.31% | ||||||
| Operating Profit Growth | % | -28.87% | +59.16% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +2.61% | +2.99% | ||||||
| Dividend Growth | % | +8.16% | +72.74% | ||||||
| Payout Ratio | % | +66.25% | +66.15% | ||||||
| FCF/Debt | x | 5.54 | 18.73 | ||||||
| Net Debt/EBITDA | x | -1.04 | -0.94 | ||||||
| EBIT/Net interest | x | 102.89 | 289.44 | ||||||
| Net debt/market cap | % | +0.34% | +0.57% | ||||||
| Net debt/Equity | x | -0.26 | -0.47 | ||||||
| Gross debt/equity | x | 0.02 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CSPC Pharmaceutical Group Limited (CSPCY)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free